Concepedia

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial

Florence Joly, Isabelle Ray‐Coquard, Michel Fabbro, Mark W. Donoghoe, Karin Boman, Akira Sugimoto, Michelle Vaughan, Alexander Reinthaller, Ignace Vergote, Gabriella Ferrandina,

Gynecologic Oncology · 2011 · 71 citations · 30 references

References

30

Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study

Franco M. Muggia, Patricia S. Braly, Mark F. Brady et al. · Journal of Clinical Oncology · 2000 · 619 citations

Medicine, Oncology, Pharmacotherapy +17

Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases

Mariana Castells, Nichole M. Tennant, David E. E. Sloane et al. · Journal of Allergy and Clinical Immunology · 2008 · 589 citations · Full text

Medicine, Immunology, Oncology +12

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

Éric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist et al. · Journal of Clinical Oncology · 2010 · 572 citations

Medicine, Oncology, Pharmacology +17

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

Martin Gore, I Fryatt, E. Wiltshaw et al. · Gynecologic Oncology · 1990 · 392 citations

Medicine, Oncology, Pharmacology +14

Clinical Features of Hypersensitivity Reactions to Carboplatin

Maurie Markman, Alexander Kennedy, Kenneth Webster et al. · Journal of Clinical Oncology · 1999 · 374 citations

Medicine, Oncology, Pharmacology +17